<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(RULE 13D-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13D-
1(A) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(A)
(AMENDMENT NO. 1)/1/
MICROCIDE PHARMACEUTICALS, INC.
-------------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
59501 8 102
-----------
(CUSIP Number)
Hope Flack
BVF Partners L.P.
333 West Wacker Drive, Suite 1600
Chicago, Illinois 60606
(312) 263-7777
--------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 15, 1997
----------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
(Continued on following pages)
(Page 1 of 7 Pages)
- -------------------------------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 2 OF 7 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
BIOTECHNOLOGY VALUE FUND, L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 WC
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
470,300
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
470,300
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
470,300
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12 [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13 4.3%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 3 OF 7 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
BVF Partners, L.P.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 OO
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
5 [_]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
886,300
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
886,300
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
886,300
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12 [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13 8.2%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 PN
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 4 OF 7 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
BVF INC.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [X]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4 WC, OO
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
5 [_]
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6 DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
886,300
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
886,300
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
886,300
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12 [_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13 8.2%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14 IA,CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 5 OF 7 PAGES
- ----------------------- ---------------------
Amendment No. 1 (the "Amendment") to the Statement on Schedule 13D, dated
August 7, 1997 (the "Statement"), filed with the Securities and Exchange
Commission on behalf of Biotechnology Value Fund, L.P., a Delaware limited
partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership
("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together
with BVF and Partners, the "Reporting Persons") with respect to the Common
Stock, no par value (the "Stock"), of Microcide Pharmaceuticals, Inc., a
Delaware corporation ("Microcide").
Item 3 is hereby amended to read in its entirety as follows:
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Since September 4, 1997, Partners, in its capacity as general partner of
BVF, has purchased on behalf of such limited partnership an aggregate number of
161,100 shares of the Stock for an aggregate consideration of $1,923,420.22,
utilizing funds provided by BVF from its working capital pursuant to the terms
of its limited partnership agreement with Partners. In addition, Partners, in
its capacity as investment manager with respect to certain managed accounts, has
purchased on behalf of such managed accounts an aggregate number of 161,400
shares of the Stock for an aggregate consideration of $1,933,842.45, utilizing
funds under management by Partners pursuant to investment management agreements
between Partners and such managed accounts.
Item 5 is hereby amended to read in its entirety as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) BVF beneficially owns 470,300 shares of the Stock, Partners
beneficially owns 886,300 shares of the Stock, and BVF Inc. beneficially owns
886,300 shares of the Stock, approximately 4.3%, 8.2% and 8.2%, respectively, of
the aggregate number of shares outstanding as of July 31, 1997 (as reported in
Microcide's quarterly statement on Form 10-Q for the quarter ending June 30,
1997).
(b) BVF shares voting and dispositive power over the 470,300 shares of the
Stock it beneficially owns with Partners. Partners and BVF Inc. share voting
and dispositive power over the 886,300 shares of the Stock they beneficially own
with, in addition to BVF, the managed accounts on whose behalf Partners, as
investment manager, purchased such shares. The managed accounts on whose behalf
Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited
liability company ("ILL10"), Palamundo, L.D.C., a limited duration company
organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities,
L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value
Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10, Palamundo, ZPG
and BVF Ltd. are collectively referred to herein as the "Accounts." The
Accounts specialize in holding
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 6 OF 7 PAGES
- ----------------------- ---------------------
biotechnology stocks for investment purposes and the business address of each is
BVF Partners L.P., 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606.
(c) Exhibit B attached hereto contains information as to all transactions
in the Stock by the Reporting Persons during the past sixty days. All such
transactions were made for cash in open market, over-the-counter transactions.
No other transactions in the Stock have been effected by the Reporting Persons
during the past sixty days.
(d) The Accounts are entitled to receive dividends and any sale proceeds
with respect to the Stock in proportion to their respective ownership interests
therein.
Item 7 is hereby amended to read in its entirety as follows:
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit A - Agreement Regarding Joint Filing
Exhibit B - Transactions in the Stock by the Reporting Persons during the
last 60 days.
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 59501 8 102 13D PAGE 7 OF 7 PAGES
- ----------------------- ---------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 10, 1997.
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
--------------------------------
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment
containing the information required by Schedule 13D, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them. The undersigned
further agree that any further amendments or supplements thereto shall also be
filed on behalf of each of them.
Dated: November 10, 1997.
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-----------------------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT B
TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
--------------------------------------------------
DURING THE PAST SIXTY DAYS
--------------------------
<TABLE>
<CAPTION>
Settlement For the
- ---------- By ------ Quantity Price per Type of Broker
Date -- Account of -------- --------- ------- ------
---- ----------- Share Trade
- --------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
09/04/97 Partners ZPG 2,400 $11.8750 Purchase INET
- --------------------------------------------------------------------------------------
09/08/97 Partners BVF 4,000 $12.7500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/08/97 Partners ILL10 2,000 $12.7500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/08/97 Partners BVF Ltd. 4,000 $12.7500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/09/97 Partners BVF 12,000 $12.5000 Purchase MLCO
- --------------------------------------------------------------------------------------
09/09/97 Partners ILL10 5,000 $12.5000 Purchase MLCO
- --------------------------------------------------------------------------------------
09/09/97 Partners PAL 3,000 $12.5000 Purchase MLCO
- --------------------------------------------------------------------------------------
09/09/97 Partners ZPG 2,000 $12.5000 Purchase MLCO
- --------------------------------------------------------------------------------------
09/09/97 Partners BVF Ltd. 8,000 $12.5000 Purchase MLCO
- --------------------------------------------------------------------------------------
09/10/97 Partners BVF Ltd. 3,200 $12.2500 Purchase PFTC
- --------------------------------------------------------------------------------------
09/11/97 Partners BVF 13,000 $12.2500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/11/97 Partners ILL10 3,000 $12.2500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/11/97 Partners BVF Ltd. 9,000 $12.2500 Purchase MLCO
- --------------------------------------------------------------------------------------
09/12/97 Partners BVF 5,400 $12.1875 Purchase INET
- --------------------------------------------------------------------------------------
09/12/97 Partners BVF Ltd. 3,000 $12.1875 Purchase INET
- --------------------------------------------------------------------------------------
10/01/97 Partners BVF 6,400 $12.2773 Purchase INET
- --------------------------------------------------------------------------------------
10/02/97 Partners BVF 300 $12.3750 Purchase INET
- --------------------------------------------------------------------------------------
10/03/97 Partners BVF 5,000 $12.2500 Purchase COWN
- --------------------------------------------------------------------------------------
10/15/97 Partners BVF Ltd. 1,800 $12.1250 Purchase INET
- --------------------------------------------------------------------------------------
10/17/97 Partners BVF Ltd. 4,500 $12.2361 Purchase INET
- --------------------------------------------------------------------------------------
10/27/97 Partners BVF 25,000 $12.2500 Purchase COWN
- --------------------------------------------------------------------------------------
10/27/97 Partners PAL 5,000 $12.2500 Purchase COWN
- --------------------------------------------------------------------------------------
10/27/97 Partners BVF Ltd. 20,000 $12.2500 Purchase COWN
- --------------------------------------------------------------------------------------
10/27/97 Partners BVF Ltd. 4,500 $12.1250 Purchase PFTC
- --------------------------------------------------------------------------------------
10/29/97 Partners BVF 45,000 $12.0000 Purchase COWN
- --------------------------------------------------------------------------------------
10/29/97 Partners ILL10 4,000 $12.0000 Purchase COWN
- --------------------------------------------------------------------------------------
10/29/97 Partners PAL 5,000 $12.0000 Purchase COWN
- --------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
Settlement For the
- ---------- By ------ Quantity Price per Type of Broker
Date -- Account of -------- --------- ------- ------
---- ----------- Share Trade
- --------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
10/29/97 Partners ZPG 3,000 $12.0000 Purchase COWN
- --------------------------------------------------------------------------------------
10/29/97 Partners BVF Ltd. 43,000 $12.0000 Purchase COWN
- --------------------------------------------------------------------------------------
10/29/97 Partners BVF 15,000 $12.0625 Purchase MLCO
- --------------------------------------------------------------------------------------
10/30/97 Partners BVF 30,000 $10.8750 Purchase COWN
- --------------------------------------------------------------------------------------
10/30/97 Partners ILL10 4,000 $10.8750 Purchase COWN
- --------------------------------------------------------------------------------------
10/30/97 Partners PAL 2,500 $10.8750 Purchase COWN
- --------------------------------------------------------------------------------------
10/30/97 Partners ZPG 2,000 $10.8750 Purchase COWN
- --------------------------------------------------------------------------------------
10/30/97 Partners BVF Ltd. 17,500 $10.8750 Purchase COWN
- --------------------------------------------------------------------------------------
</TABLE>
MLCO Merrill Lynch & Co.
INET Instinet
COWN Cowen & Company
PFTC Preferred Technologies
<PAGE>
SROS:
COMPANY DATA
COMPANY CONFORMED NAME:
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION:
IRS NUMBER:
STATE OF INCORPORATION:
FISCAL YEAR END:
BUSINESS ADDRESS
STREET 1:
STREET 2:
CITY:
STATE:
ZIP:
BUSINESS PHONE:
FORMER COMPANY
FORMER CONFORMED NAME:
DATE OF NAME CHANGE:
